Steve Lendaris

Partner

steven.lendaris@bakerbotts.com

New York

P: +1.212.408.2535 F: +1.212.259.2535
Steve Lendaris Photo

As Co-Chair of Baker Botts' Patent Counseling and Strategic IP Portfolio Development Practice group, Steve advises clients on a wide range of biotechnology-related intellectual property issues. Whether evaluating third party patents ahead of product launches for a multinational biopharma enterprise, developing patent filing strategies around new therapeutic approaches for a leading cancer research institution, or advocating for an industry-transforming sequencing company before the Patent Trial and Appeal Board, Steve's value-add is providing technically-informed and commercially-relevant legal advice that the scientists, the in-house legal team, and the C-suite can all understand.

Before attending law school, Steve performed his graduate school research on the protein-nucleic acid interactions underlying pre-messenger RNA splicing. Prior to graduate school, he was an assistant process development scientist at a large pharmaceutical company working on the production of recombinant blood clotting factors.

Related Experience

Strategic Patent Counseling and IP Diligence

  • Multinational biopharmaceutical company – IP diligence in connection with multiple technology in-license opportunities; IP diligence in connection with therapeutic antibody manufacturing; strategic patent counseling relating to therapeutic antibody products and development targets
  • Mid-size biopharmaceutical company – patent prosecution of novel antibody technologies and therapeutics; pre-litigation due diligence investigations; and strategic patent portfolio development
  • Start-up biotechnology company – development of a patent prosecution strategy and preparation of freedom to operate opinions relating to lead compounds and indications
  • Global healthcare company – corporate due diligence review facilitating an acquisition

PTAB Proceedings

  • Leading manufacturer of nucleic acid sequencing devices – filing of multiple petitions for inter partes review with the Patent Trial and Appeal Board (PTAB)
  • International pharmaceutical company – filing of multiple petitions for inter partes review with the PTAB
  • Leading manufacturer of life science research and diagnostic reagents – representation before the U.S. Patent Office in multiple ex parte reexamination proceedings

Patent Litigation & Amicus Filings

  • Leading manufacturer of nucleic acid sequencing devices – defended client in connection with allegations of patent infringement before the International Trade Commission
  • Leading manufacturer of life science research and diagnostic reagents – defense of patent infringement claim in district court concerning fluorescent labels for biomolecules
  • Global biopharmaceutical company – representation as amicus curiae in connection with the U.S. Supreme Court’s review of Bilski v. Kappos
  • Global biopharmaceutical company – representation as amicus curiae in connection with the Court of Appeals for the Federal Circuit’s review of Prometheus v. Mayo
  • International biotechnology industry organization – representation as amicus curiae in connection with the landmark AMP v. USPTO “gene patenting” case in the Southern District of New York
  • International agricultural industry organization – representation as amicus curiae in connection with the Court of Appeals for the Federal Circuit’s review of AMP v. USPTO

Awards & Community

Listed in Patent Litigation, Who's Who Legal: Life Sciences, 2016

News

Publications, Speeches & Presentations